Eli Lilly Reports Soaring Second Quarter 2026 Revenue, Raises Full-Year Guidance, and Completes Multiple Acquisitions

Eli Lilly and Company announced worldwide revenue of $23.0 billion for the second quarter of 2026, a 48% increase year-over-year. Reported EPS grew 26% to $7.94, and non-GAAP EPS increased 33% to $8.38. The company raised its full-year 2026 revenue guidance to a range of $85.0 billion to $87.0 billion and increased its underlying non-GAAP EPS guidance. Additionally, Eli Lilly completed the acquisitions of Orna Therapeutics, Ajax Therapeutics, Centessa Pharmaceuticals, and Kelonia Therapeutics during the quarter.